line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,NATHBIOGEN.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.049563,NATHBIOGEN.NS
Normalized EBITDA,2025-03-31 00:00:00,543441000.0,NATHBIOGEN.NS
Total Unusual Items,2025-03-31 00:00:00,0.0,NATHBIOGEN.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,0.0,NATHBIOGEN.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,380595000.0,NATHBIOGEN.NS
Reconciled Depreciation,2025-03-31 00:00:00,38161000.0,NATHBIOGEN.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,1355478000.0,NATHBIOGEN.NS
EBITDA,2025-03-31 00:00:00,543441000.0,NATHBIOGEN.NS
EBIT,2025-03-31 00:00:00,505280000.0,NATHBIOGEN.NS
Net Interest Income,2025-03-31 00:00:00,-104838000.0,NATHBIOGEN.NS
Interest Expense,2025-03-31 00:00:00,104838000.0,NATHBIOGEN.NS
Interest Income,2025-03-31 00:00:00,,NATHBIOGEN.NS
Normalized Income,2025-03-31 00:00:00,380595000.0,NATHBIOGEN.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,380595000.0,NATHBIOGEN.NS
Total Expenses,2025-03-31 00:00:00,3189260000.0,NATHBIOGEN.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,NATHBIOGEN.NS
Diluted Average Shares,2025-03-31 00:00:00,19165740.0,NATHBIOGEN.NS
Basic Average Shares,2025-03-31 00:00:00,19165740.0,NATHBIOGEN.NS
Diluted EPS,2025-03-31 00:00:00,20.14,NATHBIOGEN.NS
Basic EPS,2025-03-31 00:00:00,20.14,NATHBIOGEN.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,385998000.0,NATHBIOGEN.NS
Net Income Common Stockholders,2025-03-31 00:00:00,385998000.0,NATHBIOGEN.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,NATHBIOGEN.NS
Net Income,2025-03-31 00:00:00,385998000.0,NATHBIOGEN.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,385998000.0,NATHBIOGEN.NS
Net Income Extraordinary,2025-03-31 00:00:00,5403000.0,NATHBIOGEN.NS
Net Income Continuous Operations,2025-03-31 00:00:00,380595000.0,NATHBIOGEN.NS
Tax Provision,2025-03-31 00:00:00,19847000.0,NATHBIOGEN.NS
Pretax Income,2025-03-31 00:00:00,400442000.0,NATHBIOGEN.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,45458000.0,NATHBIOGEN.NS
Special Income Charges,2025-03-31 00:00:00,0.0,NATHBIOGEN.NS
Other Special Charges,2025-03-31 00:00:00,,NATHBIOGEN.NS
Write Off,2025-03-31 00:00:00,,NATHBIOGEN.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-104838000.0,NATHBIOGEN.NS
Total Other Finance Cost,2025-03-31 00:00:00,,NATHBIOGEN.NS
Interest Expense Non Operating,2025-03-31 00:00:00,104838000.0,NATHBIOGEN.NS
Interest Income Non Operating,2025-03-31 00:00:00,,NATHBIOGEN.NS
Operating Income,2025-03-31 00:00:00,459822000.0,NATHBIOGEN.NS
Operating Expense,2025-03-31 00:00:00,1833782000.0,NATHBIOGEN.NS
Other Operating Expenses,2025-03-31 00:00:00,300866000.0,NATHBIOGEN.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,38161000.0,NATHBIOGEN.NS
Amortization,2025-03-31 00:00:00,,NATHBIOGEN.NS
Depreciation Income Statement,2025-03-31 00:00:00,38161000.0,NATHBIOGEN.NS
Research And Development,2025-03-31 00:00:00,,NATHBIOGEN.NS
Selling General And Administration,2025-03-31 00:00:00,1169717000.0,NATHBIOGEN.NS
Selling And Marketing Expense,2025-03-31 00:00:00,1169717000.0,NATHBIOGEN.NS
General And Administrative Expense,2025-03-31 00:00:00,,NATHBIOGEN.NS
Rent And Landing Fees,2025-03-31 00:00:00,,NATHBIOGEN.NS
Gross Profit,2025-03-31 00:00:00,2293604000.0,NATHBIOGEN.NS
Cost Of Revenue,2025-03-31 00:00:00,1355478000.0,NATHBIOGEN.NS
Total Revenue,2025-03-31 00:00:00,3649082000.0,NATHBIOGEN.NS
Operating Revenue,2025-03-31 00:00:00,3649082000.0,NATHBIOGEN.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,NATHBIOGEN.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.05106,NATHBIOGEN.NS
Normalized EBITDA,2024-03-31 00:00:00,504883000.0,NATHBIOGEN.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,NATHBIOGEN.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,NATHBIOGEN.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,361697000.0,NATHBIOGEN.NS
Reconciled Depreciation,2024-03-31 00:00:00,32612000.0,NATHBIOGEN.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,1335722000.0,NATHBIOGEN.NS
EBITDA,2024-03-31 00:00:00,504883000.0,NATHBIOGEN.NS
EBIT,2024-03-31 00:00:00,472271000.0,NATHBIOGEN.NS
Net Interest Income,2024-03-31 00:00:00,-91112000.0,NATHBIOGEN.NS
Interest Expense,2024-03-31 00:00:00,91112000.0,NATHBIOGEN.NS
Interest Income,2024-03-31 00:00:00,3224000.0,NATHBIOGEN.NS
Normalized Income,2024-03-31 00:00:00,361697000.0,NATHBIOGEN.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,361697000.0,NATHBIOGEN.NS
Total Expenses,2024-03-31 00:00:00,2860244000.0,NATHBIOGEN.NS
Rent Expense Supplemental,2024-03-31 00:00:00,105906000.0,NATHBIOGEN.NS
Diluted Average Shares,2024-03-31 00:00:00,18565370.0,NATHBIOGEN.NS
Basic Average Shares,2024-03-31 00:00:00,18565370.0,NATHBIOGEN.NS
Diluted EPS,2024-03-31 00:00:00,21.34,NATHBIOGEN.NS
Basic EPS,2024-03-31 00:00:00,21.34,NATHBIOGEN.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,396185000.0,NATHBIOGEN.NS
Net Income Common Stockholders,2024-03-31 00:00:00,396185000.0,NATHBIOGEN.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,NATHBIOGEN.NS
Net Income,2024-03-31 00:00:00,396185000.0,NATHBIOGEN.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,396185000.0,NATHBIOGEN.NS
Net Income Extraordinary,2024-03-31 00:00:00,34488000.0,NATHBIOGEN.NS
Net Income Continuous Operations,2024-03-31 00:00:00,361697000.0,NATHBIOGEN.NS
Tax Provision,2024-03-31 00:00:00,19462000.0,NATHBIOGEN.NS
Pretax Income,2024-03-31 00:00:00,381159000.0,NATHBIOGEN.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,6266000.0,NATHBIOGEN.NS
Special Income Charges,2024-03-31 00:00:00,0.0,NATHBIOGEN.NS
Other Special Charges,2024-03-31 00:00:00,-34498000.0,NATHBIOGEN.NS
Write Off,2024-03-31 00:00:00,248000.0,NATHBIOGEN.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-91112000.0,NATHBIOGEN.NS
Total Other Finance Cost,2024-03-31 00:00:00,5761000.0,NATHBIOGEN.NS
Interest Expense Non Operating,2024-03-31 00:00:00,91112000.0,NATHBIOGEN.NS
Interest Income Non Operating,2024-03-31 00:00:00,3224000.0,NATHBIOGEN.NS
Operating Income,2024-03-31 00:00:00,466005000.0,NATHBIOGEN.NS
Operating Expense,2024-03-31 00:00:00,1524522000.0,NATHBIOGEN.NS
Other Operating Expenses,2024-03-31 00:00:00,279395000.0,NATHBIOGEN.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,32612000.0,NATHBIOGEN.NS
Amortization,2024-03-31 00:00:00,16056000.0,NATHBIOGEN.NS
Depreciation Income Statement,2024-03-31 00:00:00,32612000.0,NATHBIOGEN.NS
Research And Development,2024-03-31 00:00:00,112763000.0,NATHBIOGEN.NS
Selling General And Administration,2024-03-31 00:00:00,930007000.0,NATHBIOGEN.NS
Selling And Marketing Expense,2024-03-31 00:00:00,930007000.0,NATHBIOGEN.NS
General And Administrative Expense,2024-03-31 00:00:00,72858000.0,NATHBIOGEN.NS
Rent And Landing Fees,2024-03-31 00:00:00,34589000.0,NATHBIOGEN.NS
Gross Profit,2024-03-31 00:00:00,1990527000.0,NATHBIOGEN.NS
Cost Of Revenue,2024-03-31 00:00:00,1335722000.0,NATHBIOGEN.NS
Total Revenue,2024-03-31 00:00:00,3326249000.0,NATHBIOGEN.NS
Operating Revenue,2024-03-31 00:00:00,3326249000.0,NATHBIOGEN.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-17151.3,NATHBIOGEN.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.0323,NATHBIOGEN.NS
Normalized EBITDA,2023-03-31 00:00:00,488030000.0,NATHBIOGEN.NS
Total Unusual Items,2023-03-31 00:00:00,-531000.0,NATHBIOGEN.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-531000.0,NATHBIOGEN.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,350114000.0,NATHBIOGEN.NS
Reconciled Depreciation,2023-03-31 00:00:00,30123000.0,NATHBIOGEN.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,1146123000.0,NATHBIOGEN.NS
EBITDA,2023-03-31 00:00:00,487499000.0,NATHBIOGEN.NS
EBIT,2023-03-31 00:00:00,457376000.0,NATHBIOGEN.NS
Net Interest Income,2023-03-31 00:00:00,-103408000.0,NATHBIOGEN.NS
Interest Expense,2023-03-31 00:00:00,95733000.0,NATHBIOGEN.NS
Interest Income,2023-03-31 00:00:00,179000.0,NATHBIOGEN.NS
Normalized Income,2023-03-31 00:00:00,350627848.7,NATHBIOGEN.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,350114000.0,NATHBIOGEN.NS
Total Expenses,2023-03-31 00:00:00,2553275000.0,NATHBIOGEN.NS
Rent Expense Supplemental,2023-03-31 00:00:00,94657000.0,NATHBIOGEN.NS
Diluted Average Shares,2023-03-31 00:00:00,19004000.0,NATHBIOGEN.NS
Basic Average Shares,2023-03-31 00:00:00,19004000.0,NATHBIOGEN.NS
Diluted EPS,2023-03-31 00:00:00,18.43,NATHBIOGEN.NS
Basic EPS,2023-03-31 00:00:00,18.43,NATHBIOGEN.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,350114000.0,NATHBIOGEN.NS
Net Income Common Stockholders,2023-03-31 00:00:00,350114000.0,NATHBIOGEN.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,NATHBIOGEN.NS
Net Income,2023-03-31 00:00:00,350114000.0,NATHBIOGEN.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,350114000.0,NATHBIOGEN.NS
Net Income Extraordinary,2023-03-31 00:00:00,0.0,NATHBIOGEN.NS
Net Income Continuous Operations,2023-03-31 00:00:00,350114000.0,NATHBIOGEN.NS
Tax Provision,2023-03-31 00:00:00,11529000.0,NATHBIOGEN.NS
Pretax Income,2023-03-31 00:00:00,361643000.0,NATHBIOGEN.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,989000.0,NATHBIOGEN.NS
Special Income Charges,2023-03-31 00:00:00,-531000.0,NATHBIOGEN.NS
Other Special Charges,2023-03-31 00:00:00,-49000.0,NATHBIOGEN.NS
Write Off,2023-03-31 00:00:00,580000.0,NATHBIOGEN.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-103408000.0,NATHBIOGEN.NS
Total Other Finance Cost,2023-03-31 00:00:00,7854000.0,NATHBIOGEN.NS
Interest Expense Non Operating,2023-03-31 00:00:00,95733000.0,NATHBIOGEN.NS
Interest Income Non Operating,2023-03-31 00:00:00,179000.0,NATHBIOGEN.NS
Operating Income,2023-03-31 00:00:00,460362000.0,NATHBIOGEN.NS
Operating Expense,2023-03-31 00:00:00,1407152000.0,NATHBIOGEN.NS
Other Operating Expenses,2023-03-31 00:00:00,723372000.0,NATHBIOGEN.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,30123000.0,NATHBIOGEN.NS
Amortization,2023-03-31 00:00:00,16409000.0,NATHBIOGEN.NS
Depreciation Income Statement,2023-03-31 00:00:00,13714000.0,NATHBIOGEN.NS
Research And Development,2023-03-31 00:00:00,93713000.0,NATHBIOGEN.NS
Selling General And Administration,2023-03-31 00:00:00,290877000.0,NATHBIOGEN.NS
Selling And Marketing Expense,2023-03-31 00:00:00,234072000.0,NATHBIOGEN.NS
General And Administrative Expense,2023-03-31 00:00:00,56805000.0,NATHBIOGEN.NS
Rent And Landing Fees,2023-03-31 00:00:00,30988000.0,NATHBIOGEN.NS
Gross Profit,2023-03-31 00:00:00,1867514000.0,NATHBIOGEN.NS
Cost Of Revenue,2023-03-31 00:00:00,1146123000.0,NATHBIOGEN.NS
Total Revenue,2023-03-31 00:00:00,3013637000.0,NATHBIOGEN.NS
Operating Revenue,2023-03-31 00:00:00,3013637000.0,NATHBIOGEN.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,-265947000.0,NATHBIOGEN.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.3,NATHBIOGEN.NS
Normalized EBITDA,2022-03-31 00:00:00,384247000.0,NATHBIOGEN.NS
Total Unusual Items,2022-03-31 00:00:00,-886490000.0,NATHBIOGEN.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,-886490000.0,NATHBIOGEN.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,-673853000.0,NATHBIOGEN.NS
Reconciled Depreciation,2022-03-31 00:00:00,30841000.0,NATHBIOGEN.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,1239684000.0,NATHBIOGEN.NS
EBITDA,2022-03-31 00:00:00,-502243000.0,NATHBIOGEN.NS
EBIT,2022-03-31 00:00:00,-533084000.0,NATHBIOGEN.NS
Net Interest Income,2022-03-31 00:00:00,-95512000.0,NATHBIOGEN.NS
Interest Expense,2022-03-31 00:00:00,101253000.0,NATHBIOGEN.NS
Interest Income,2022-03-31 00:00:00,10926000.0,NATHBIOGEN.NS
Normalized Income,2022-03-31 00:00:00,-53310000.0,NATHBIOGEN.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,-673853000.0,NATHBIOGEN.NS
Total Expenses,2022-03-31 00:00:00,2437505000.0,NATHBIOGEN.NS
Rent Expense Supplemental,2022-03-31 00:00:00,114416000.0,NATHBIOGEN.NS
Diluted Average Shares,2022-03-31 00:00:00,19004000.0,NATHBIOGEN.NS
Basic Average Shares,2022-03-31 00:00:00,19004000.0,NATHBIOGEN.NS
Diluted EPS,2022-03-31 00:00:00,-35.55,NATHBIOGEN.NS
Basic EPS,2022-03-31 00:00:00,-35.55,NATHBIOGEN.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,-673853000.0,NATHBIOGEN.NS
Net Income Common Stockholders,2022-03-31 00:00:00,-673853000.0,NATHBIOGEN.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,NATHBIOGEN.NS
Net Income,2022-03-31 00:00:00,-673853000.0,NATHBIOGEN.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,-673853000.0,NATHBIOGEN.NS
Net Income Extraordinary,2022-03-31 00:00:00,0.0,NATHBIOGEN.NS
Net Income Continuous Operations,2022-03-31 00:00:00,-673853000.0,NATHBIOGEN.NS
Tax Provision,2022-03-31 00:00:00,39516000.0,NATHBIOGEN.NS
Pretax Income,2022-03-31 00:00:00,-634337000.0,NATHBIOGEN.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,973000.0,NATHBIOGEN.NS
Special Income Charges,2022-03-31 00:00:00,-886490000.0,NATHBIOGEN.NS
Other Special Charges,2022-03-31 00:00:00,886415000.0,NATHBIOGEN.NS
Write Off,2022-03-31 00:00:00,75000.0,NATHBIOGEN.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-95512000.0,NATHBIOGEN.NS
Total Other Finance Cost,2022-03-31 00:00:00,5185000.0,NATHBIOGEN.NS
Interest Expense Non Operating,2022-03-31 00:00:00,101253000.0,NATHBIOGEN.NS
Interest Income Non Operating,2022-03-31 00:00:00,10926000.0,NATHBIOGEN.NS
Operating Income,2022-03-31 00:00:00,346100000.0,NATHBIOGEN.NS
Operating Expense,2022-03-31 00:00:00,1197821000.0,NATHBIOGEN.NS
Other Operating Expenses,2022-03-31 00:00:00,530441000.0,NATHBIOGEN.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,30841000.0,NATHBIOGEN.NS
Amortization,2022-03-31 00:00:00,16055000.0,NATHBIOGEN.NS
Depreciation Income Statement,2022-03-31 00:00:00,14786000.0,NATHBIOGEN.NS
Research And Development,2022-03-31 00:00:00,88852000.0,NATHBIOGEN.NS
Selling General And Administration,2022-03-31 00:00:00,264603000.0,NATHBIOGEN.NS
Selling And Marketing Expense,2022-03-31 00:00:00,198149000.0,NATHBIOGEN.NS
General And Administrative Expense,2022-03-31 00:00:00,66454000.0,NATHBIOGEN.NS
Rent And Landing Fees,2022-03-31 00:00:00,30344000.0,NATHBIOGEN.NS
Gross Profit,2022-03-31 00:00:00,1543921000.0,NATHBIOGEN.NS
Cost Of Revenue,2022-03-31 00:00:00,1239684000.0,NATHBIOGEN.NS
Total Revenue,2022-03-31 00:00:00,2783605000.0,NATHBIOGEN.NS
Operating Revenue,2022-03-31 00:00:00,2783605000.0,NATHBIOGEN.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,NATHBIOGEN.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,NATHBIOGEN.NS
Normalized EBITDA,2021-03-31 00:00:00,,NATHBIOGEN.NS
Total Unusual Items,2021-03-31 00:00:00,,NATHBIOGEN.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,NATHBIOGEN.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,NATHBIOGEN.NS
Reconciled Depreciation,2021-03-31 00:00:00,,NATHBIOGEN.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,NATHBIOGEN.NS
EBITDA,2021-03-31 00:00:00,,NATHBIOGEN.NS
EBIT,2021-03-31 00:00:00,,NATHBIOGEN.NS
Net Interest Income,2021-03-31 00:00:00,,NATHBIOGEN.NS
Interest Expense,2021-03-31 00:00:00,,NATHBIOGEN.NS
Interest Income,2021-03-31 00:00:00,12136000.0,NATHBIOGEN.NS
Normalized Income,2021-03-31 00:00:00,,NATHBIOGEN.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,NATHBIOGEN.NS
Total Expenses,2021-03-31 00:00:00,,NATHBIOGEN.NS
Rent Expense Supplemental,2021-03-31 00:00:00,151241000.0,NATHBIOGEN.NS
Diluted Average Shares,2021-03-31 00:00:00,,NATHBIOGEN.NS
Basic Average Shares,2021-03-31 00:00:00,,NATHBIOGEN.NS
Diluted EPS,2021-03-31 00:00:00,,NATHBIOGEN.NS
Basic EPS,2021-03-31 00:00:00,,NATHBIOGEN.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,NATHBIOGEN.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,NATHBIOGEN.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,NATHBIOGEN.NS
Net Income,2021-03-31 00:00:00,,NATHBIOGEN.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,NATHBIOGEN.NS
Net Income Extraordinary,2021-03-31 00:00:00,,NATHBIOGEN.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,NATHBIOGEN.NS
Tax Provision,2021-03-31 00:00:00,,NATHBIOGEN.NS
Pretax Income,2021-03-31 00:00:00,,NATHBIOGEN.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,NATHBIOGEN.NS
Special Income Charges,2021-03-31 00:00:00,,NATHBIOGEN.NS
Other Special Charges,2021-03-31 00:00:00,-718000.0,NATHBIOGEN.NS
Write Off,2021-03-31 00:00:00,809000.0,NATHBIOGEN.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,NATHBIOGEN.NS
Total Other Finance Cost,2021-03-31 00:00:00,9638000.0,NATHBIOGEN.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,NATHBIOGEN.NS
Interest Income Non Operating,2021-03-31 00:00:00,12136000.0,NATHBIOGEN.NS
Operating Income,2021-03-31 00:00:00,,NATHBIOGEN.NS
Operating Expense,2021-03-31 00:00:00,,NATHBIOGEN.NS
Other Operating Expenses,2021-03-31 00:00:00,,NATHBIOGEN.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,NATHBIOGEN.NS
Amortization,2021-03-31 00:00:00,15978718.0,NATHBIOGEN.NS
Depreciation Income Statement,2021-03-31 00:00:00,,NATHBIOGEN.NS
Research And Development,2021-03-31 00:00:00,91541000.0,NATHBIOGEN.NS
Selling General And Administration,2021-03-31 00:00:00,,NATHBIOGEN.NS
Selling And Marketing Expense,2021-03-31 00:00:00,,NATHBIOGEN.NS
General And Administrative Expense,2021-03-31 00:00:00,50918000.0,NATHBIOGEN.NS
Rent And Landing Fees,2021-03-31 00:00:00,30778000.0,NATHBIOGEN.NS
Gross Profit,2021-03-31 00:00:00,,NATHBIOGEN.NS
Cost Of Revenue,2021-03-31 00:00:00,,NATHBIOGEN.NS
Total Revenue,2021-03-31 00:00:00,,NATHBIOGEN.NS
Operating Revenue,2021-03-31 00:00:00,,NATHBIOGEN.NS
